Abstract
Background: The purpose of this study was to evaluate the prognostic value of the maximum standard uptake value (SUV<sub>max</sub>) measured by 18-F fluoro-2-deoxy-d-glucose (F-18 FDG) positron emission tomography/computed tomography (PET/CT) in newly diagnosed small cell lung cancer (SCLC) patients. Methods: We reviewed the medical records of newly diagnosed SCLC patients who were given a histological diagnosis from June 2008 to June 2014. 82 patients who satisfied the inclusion criteria were enrolled for final analysis (male n = 75, female n = 7). The relationship between SUV<sub>max</sub> and overall survival (OS) and progression-free survival (PFS) was evaluated. Results: Median follow-up was 25.0 months (range 11.6-55.5 months). The median OS was 11.2 months (range 1.6-55.5 months), and the median PFS was 6.1 months (range 0.9-55.5 months). Survival analysis showed no statistical differences in OS and PFS between high and low SUV<sub>max</sub> groups. Conclusion: This study does not support the use of SUV<sub>max</sub> of pretreatment F-18 FDG PET/CT scans as a prognostic tool for patients with SCLC.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
